Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstra
04.08.2022 - Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded ...
Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tov
Investegate announcements from Olink Proteomics AB, Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines...